Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.

MLA

Chen, Allen R., et al. “Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.” Blood, vol. 110, no. 11, Nov. 2007, p. 1896. EBSCOhost, https://doi.org/10.1182/blood.V110.11.1896.1896.

APA

Chen, A. R., Hutchison, R., Hess, A., Gardner, S., Trippett, T., de Alarcon, P., Hogan, S., Mitchell, J., Massey, V., Constine, L. S., Chen, L., & Schwartz, C. L. (2007). Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study. Blood, 110(11), 1896. https://doi.org/10.1182/blood.V110.11.1896.1896

Chicago

Chen, Allen R., Robert Hutchison, Allan Hess, Sharon Gardner, Tanya Trippett, Pedro de Alarcon, Shirley Hogan, et al. 2007. “Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.” Blood 110 (11): 1896. doi:10.1182/blood.V110.11.1896.1896.